Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Amonkar, M. [3 ]
Fuchs, C. S. [4 ]
Alsina, M. [5 ,6 ]
Ozguroglu, M. [7 ]
Bang, Y-J. [8 ]
Chung, H. C. [9 ]
Muro, K. [10 ]
Goekkurt, E. [11 ]
Benson, A. [12 ]
Sun, W. [13 ]
Wainberg, Z. A. [14 ]
Norquist, J. [3 ]
Chen, X. [3 ]
Shih, C-S. [3 ]
Shitara, K. [15 ]
机构：
[1] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[4] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[5] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain
[7] Istanbul Univ Cerrahpasa, Clin Trial Unit, Cerrahpasa Sch Med, Internal Med,Med Oncol, Istanbul, Turkey
[8] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
[9] Yonsei Univ, Med Oncol, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[10] Aichi Canc Ctr Hosp, Clin Oncol, Nagoya, Aichi, Japan
[11] Univ Canc Ctr Hamburg, HOPE, North German Trial Ctr Innovat Oncol NIO, Hamburg, Germany
[12] Northwestern Med Fac Fdn, Hematol Oncol, Chicago, IL USA
[13] Univ Kansas, Internal Med, Med Oncol, Westwood, KS USA
[14] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol & Oncol, Los Angeles, CA 90095 USA
[15] Natl Canc Ctr Hosp, Gastrointestinal Oncol, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
791P
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [41] KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).
    Bratland, Ase
    Munoz-Couselo, Eva
    Mortier, Laurent
    Roshdy, Osama
    Gonzalez, Rene
    Schachter, Jacob
    Arance, Ana Maria
    Grange, Florent
    Meyer, Nicolas
    Joshi, Abhishek Jagdish
    Billan, Salem
    Hughes, Brett Gordon Maxwell
    Grob, Jean-Jacques
    Ramakrishnan, Karthik
    Zhang, Eric
    Gumuscu, Burak
    Swaby, Ramona F.
    Gutzmer, Ralf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    Acosta, A. De Jesus
    Miller, W. H., Jr.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Amonkar, M.
    Xu, L.
    Jin, F.
    Norwood, K.
    Maio, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S760 - S761
  • [43] Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Andre, T.
    Amonkar, M.
    Norquist, J.
    Shiu, K-K.
    Kim, T. W.
    Jensen, B. V.
    Jensen, L. H.
    Punt, C. J.
    Smith, D.
    Garcia-Carbonero, R.
    Sevilla, I.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Diaz, L. A.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Le, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S409
  • [44] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649
    Elimova, Elena
    Wyrwicz, Lucjan
    Blum, Steven I.
    Xiao, Hong
    Li, Mingshun
    Kondo, Kaoru
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [45] Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC)
    Yoo, Changhoon
    Finn, Richard S.
    Mpen, Heinz-Josef Klu Spacing Diaeresis
    Kelley, Robin Kate
    Vogel, Arndt
    Furuse, Junji
    Ren, Zhenggang
    Yau, Thomas
    Chan, Stephen Lam
    Ozaka, Masato
    Oh, Sang Cheul
    Gu, Shanzhi
    Park, Joon Oh
    Valle, Juan W.
    Edeline, Julien
    Kamble, Shital
    Norquist, Josephine M.
    Yu, Li
    Malhotra, Usha
    Ueno, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer
    Daniel, Catenacci, V
    Zev, Wainberg
    Charles, Fuchs S.
    Marcelo, Garrido
    Bang Yung-Jue
    Kei, Muro
    Mary, Savage
    Wang Jiangdian
    Minori, Koshiji
    Rita, Dalal P.
    Yoon-Koo, Kang
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
    Van Cutsem, E.
    Valderrama, A.
    Bang, Y. -J.
    Fuchs, C. S.
    Shitara, K.
    Janjigian, Y. Y.
    Qin, S.
    Larson, T. G.
    Shankaran, V.
    Stein, S.
    Norquist, J. M.
    Kher, U.
    Shah, S.
    Alsina, M.
    ESMO OPEN, 2021, 6 (04)
  • [48] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Tabernero, J.
    Bang, Y.
    Van Cutsem, E.
    Fuchs, C.
    Janjigian, Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Qin, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
  • [49] Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Kamble, Shital
    Norquist, Josephine M.
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 506 - 506
  • [50] Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study
    Chan, A. T. C.
    Lee, H. F. V.
    Hong, R-L.
    Ahn, M-J.
    Chong, W. Q.
    Kim, S-B.
    Fuang, H. G.
    Caguioa, P. B.
    Ngamphaiboon, N.
    Ho, C.
    Aziz, M. A. S. Abdul
    Ng, Q. S.
    Yen, C. J.
    Soparattanapaisarn, N.
    Ngan, R.
    Kho, S. K.
    Wang, L.
    Swaby, R.
    Saraf, S.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1452 - S1452
12345